MS
CRL icon

Murray Stahl’s Charles River Laboratories CRL Stock Holding History

Murray Stahl’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.61M Sell
7,103
-5,089
-42% -$906K 0.02% 129
2026
Q1 		$2.1M Sell
12,192
-388
-3% -$71.9K 0.02% 116
2025
Q4 		$2.51M Sell
12,580
-329
-3% -$59.7K 0.03% 99
2025
Q3 		$2.02M Sell
12,909
-9,351
-42% -$1.49M 0.02% 117
2025
Q2 		$3.38M Sell
22,260
-12,026
-35% -$1.6M 0.04% 89
2025
Q1 		$5.16M Sell
34,286
-25,554
-43% -$4.28M 0.06% 68
2024
Q4 		$11M Sell
59,840
-54,922
-48% -$10.6M 0.14% 48
2024
Q3 		$22.6M Sell
114,762
-45,619
-28% -$9.48M 0.34% 34
2024
Q2 		$33.1M Buy
160,381
+1,170
+0.7% +$265K 0.58% 20
2024
Q1 		$43.1M Sell
159,211
-23,453
-13% -$5.6M 0.82% 15
2023
Q4 		$43.2M Sell
182,664
-31,571
-15% -$6.21M 0.9% 17
2023
Q3 		$42M Sell
214,235
-18,265
-8% -$3.75M 0.83% 19
2023
Q2 		$48.9M Sell
232,500
-14,468
-6% -$2.88M 1.05% 15
2023
Q1 		$49.8M Sell
246,968
-13,125
-5% -$2.97M 0.96% 16
2022
Q4 		$56.7M Sell
260,093
-24,296
-9% -$5.31M 0.94% 14
2022
Q3 		$56M Sell
284,389
-14,585
-5% -$3.15M 1.13% 11
2022
Q2 		$64M Buy
298,974
+23,735
+9% +$5.8M 1.34% 12
2022
Q1 		$78.2M Buy
275,239
+47,933
+21% +$14.8M 1.57% 10
2021
Q4 		$85.6M Buy
227,306
+19,514
+9% +$7.58M 1.89% 7
2021
Q3 		$85.7M Buy
207,792
+11,038
+6% +$4.58M 2% 7
2021
Q2 		$72.8M Buy
196,754
+75,962
+63% +$25.4M 1.48% 8
2021
Q1 		$35M Buy
120,792
+9,074
+8% +$2.52M 0.79% 19
2020
Q4 		$27.9M Sell
111,718
-2,889
-3% -$688K 0.93% 21
2020
Q3 		$26M Buy
114,607
+654
+0.6% +$136K 1.04% 20
2020
Q2 		$19.9M Buy
113,953
+75,262
+195% +$12M 0.72% 23
2020
Q1 		$4.88M Buy
+38,691
New +$5.8M 0.22% 53

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Murray Stahl's CRL Position: Q2 2026 in Review

Murray Stahl reduced its Charles River Laboratories (CRL) stake by 42% in Q2 2026, selling an estimated $906K and leaving 7,103 shares worth $1.61M. The position accounts for 0.02% of the portfolio, ranked #129.

Murray Stahl first reported a position in CRL in Q1 2020 and has held it in 26 quarters since. The position peaked at $85.7M in Q3 2021. 563 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Murray Stahl held 7,103 shares of Charles River Laboratories worth $1.61M as of Q2 2026.
  • Murray Stahl sold 5,089 Charles River Laboratories shares in Q2 2026, an estimated $906K.
  • Charles River Laboratories made up 0.02% of Murray Stahl's portfolio in Q2 2026, its #129 holding.
  • Murray Stahl first reported a position in Charles River Laboratories in Q1 2020 and has held it in 26 quarters since.
  • Murray Stahl's Charles River Laboratories position peaked at $85.7M in Q3 2021.
  • 563 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Horizon Kinetics Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.